Furthermore, we found that 5 immune inhibitors (KDR, TIGIT, VTCN1, LAG3 and ADORA2A) and 2 immune stimulators (ICOS and TNFRSF25) were significantly associated with HIC2 in gliomas (Figure S5E). Here, VTCN1 is linked to central nervous system cancer.